Novartis displays a mixed bag of financial and operational performance. The company continually strengthens its position through various wealth advisors acquiring the company's shares. It outperformed underlying earnings growth over the last three years, with its Q4 earnings and sales beating the market, subsequently leading to an unusually high trading volume. Despite facing competition for its primary drug, the company still saw strong drug sales, even raising its dividend. However, its stock was down despite Q3 beat, taking an $800 million write-down, and was downgraded by HSBC due to conservative capital deployment failing to offset LOE concerns. Yet, it showed promising signs with its 16% sales growth in Q4 and projected continued momentum into 2025, and a successful gene therapy to treat SMA. In partnerships, a licensing agreement with PTC Therapeutics soared the latter's stocks, while collaboration with Schrödinger could be worth up to $2.5 billion. But, the company sacrifices a flat base on lagging sales despite revealing strong 2024 financial performance and innovation milestones. Interestingly, it has been called an oversold and underappreciated stock ready to be picked up.
Novartis Stocks News Analytics from Mon, 08 Jul 2024 07:00:00 GMT to Sat, 01 Feb 2025 22:53:50 GMT -
Rating 4
- Innovation 6
- Information 7
- Rumor -2
